Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder Quiver Quantitative, Inc. - Mon Dec 16, 5:24PM CST

Daré Bioscience announces plans for a Phase 3 study of Sildenafil Cream for treating female sexual arousal disorder (FSAD).Quiver AI SummaryDaré Bioscience, in collaboration with Strategic Science &...

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) GlobeNewswire - Mon Dec 16, 7:00AM CST

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% GlobeNewswire - Tue Dec 10, 7:00AM CST

DARE : 3.26 (-1.21%)
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 GlobeNewswire - Wed Dec 4, 7:00AM CST

DARE : 3.26 (-1.21%)
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update GlobeNewswire - Thu Nov 14, 3:01PM CST

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites GlobeNewswire - Wed Nov 13, 7:00AM CST

DARE : 3.26 (-1.21%)
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024 GlobeNewswire - Thu Nov 7, 7:00AM CST

DARE : 3.26 (-1.21%)
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health GlobeNewswire - Wed Oct 23, 11:30AM CDT

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC GlobeNewswire - Mon Oct 21, 7:05AM CDT

DARE : 3.26 (-1.21%)
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update Globe Newswire - Tue Aug 9, 2022

June 30, 2022: $32.1 million in cash and cash equivalentsJuly 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million...

DARE : 3.26 (-1.21%)

Barchart Exclusives

Is Rumble Stock a Buy, Sell, or Hold After a $775 Million Investment? Barchart - 26 minutes ago
Rumble’s stock has shot up following an investment agreement with a giant crypto firm. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot